High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

NCT04247633 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

578

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Palbociclib

Sponsor

Samsung Medical Center

Collaborators

[object Object]